Can GLP-1s Help Skin Conditions Like Psoriasis?
GLP-1s Keep Surprising Us. Now It’s Skin Disease.
Dermatologists are reporting something they didn’t expect: patients who started a GLP-1 for weight or blood sugar are walking in with clearer skin. A new report pulls the early evidence together.
Every few months the GLP-1 story gets bigger. These drugs started as diabetes medications, became weight-loss medications, and now researchers are chasing signals in the heart, the kidneys, the liver, and the brain. According to a Medscape Medical News report published July 9, 2026, the newest place they’re looking is the skin.
The report describes dermatologists watching patients with psoriasis and hidradenitis suppurativa — two of the harder-to-treat chronic inflammatory skin conditions — improve after starting GLP-1 therapy that had been prescribed for something else. In some psoriasis cases described in the report, clinicians observed rapid or near-complete plaque clearance.
That kind of anecdote is easy to dismiss on its own. What makes this moment different is that the anecdotes now have company. Here’s how the GLP-1 story kept widening — tap through it.
What the research shows so far
The strongest piece is a phase 3b randomized trial. In TOGETHER-PsO, published in JAMA Dermatology in May 2026, 274 adults with moderate-to-severe plaque psoriasis and overweight or obesity were randomized to the IL-17 inhibitor ixekizumab either with or without tirzepatide. At week 36, 27.1% of the combination group hit the primary endpoint — complete skin clearance (PASI 100) and at least 10% weight loss — against 5.8% on the biologic alone. Read that endpoint carefully: it bundles skin and weight together, so a weight-loss drug has a built-in advantage on it. The more interesting number is that complete skin clearance on its own was also higher in the combination arm. Worth naming plainly: the trial was run by Eli Lilly, which makes both drugs.
There is a genetic signal too, and cohort data. But the evidence is not equally deep for every condition. Switch between them below.
Why would a metabolic drug touch the skin?
The Medscape report frames this as part of a twenty-year shift in how dermatology thinks about fat tissue. Medical schools once taught that fat had nothing to do with skin disease. That idea has been steadily overturned as the field learned how body-wide inflammation drives skin conditions — and that fat tissue is not inert storage but an active source of inflammatory signaling.
That leaves the central question open, and the researchers are careful about it. The authors of the genetics paper say so directly: it is not yet clear whether any benefit comes from GLP-1 signaling acting on the immune system, or from the indirect consequences of better metabolic control. And there is a thread here worth pulling for anyone in this community: . Tap each theory.
Both mechanisms are plausible. Both may be true at once. And right now nobody can tell them apart: the 2026 systematic review of GLP-1s in hidradenitis suppurativa concludes exactly that — from the existing data, the weight-dependent and weight-independent effects cannot be separated. The trials being planned, including psoriasis studies using GLP-1s alone, are built to answer that question.
The anecdotes now have company — a randomized trial, a genetics paper, a cohort study, all pointing the same direction. Pointing is not proving.
The state of play, July 2026What this means if you’re listening from the diabetes world
Skin conditions and diabetes travel together more often than people realize, and GLP-1s are already a constant topic in this community — for type 2, for weight management, and in ongoing research conversations around type 1. This report doesn’t change what anyone should do today. GLP-1 medications are not approved to treat psoriasis, hidradenitis suppurativa, or any skin condition, and the dermatologists quoted say plainly that controlled trials are needed before formal recommendations exist.
What it does show is a pattern worth watching. A class of drugs built for blood sugar keeps turning up benefits in places nobody was looking. Whether the skin findings hold up in randomized trials is a question the next few years will answer. If your skin, your weight, and your glucose are all part of your health picture — and for a lot of people in this community, they are — this is a conversation to have with your doctor, not a change to make on your own.
Psoriasis. Lebwohl M, Blauvelt A, Kartman CE, et al. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial (TOGETHER-PsO). JAMA Dermatology, May 15, 2026. Sponsored by Eli Lilly, maker of both study drugs. · Ramessur R, Arham AGA, Saklatvala J, et al. Genetic proxies of GLP1R expression are associated with lower risk of psoriasis and psoriatic arthritis. British Journal of Dermatology, 2026.
Hidradenitis suppurativa. Systematic review, American Journal of Clinical Dermatology, 2026. · Gouvrion L, Delage M, Villani AP, et al. Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa. JAMA Dermatology, August 2025. · Gupta R, Cesar L, Micheletti R, Fang V. Patient-reported outcomes of GLP-1 agonists on hidradenitis suppurativa severity. JAAD International, 2025.
Both conditions. Ching LM, Guirguis CA, Iskandar NL, Tung JK. Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists. JAAD International, 2025.
Atopic dermatitis. Association of glucagon-like peptide-1 agonist use with atopic dermatitis in obese patients: a retrospective cohort study. Journal of the American Academy of Dermatology, 2025.
How to read this evidence. One randomized trial exists, and only in psoriasis. Everything else is observational: cohort studies and surveys show association, not cause. Mendelian randomization estimates the effect of lifelong genetic differences in GLP-1 receptor expression, which is not the same as the effect of taking one of these drugs. Across every study here, researchers say the same thing — nobody can yet separate what the drug does to inflammation from what the weight loss does. GLP-1 medications are not FDA-approved to treat psoriasis, hidradenitis suppurativa, atopic dermatitis, or any other skin condition.
This post is for educational purposes only and is not medical advice. Nothing here is a recommendation to start, stop, or change any medication. Talk with your doctor before making any changes to your care.
Listen to the Juicebox Podcast
Conversations about diabetes, five days a week, since 2015.
Read the full disclaimer
